Phibro Animal Health (NASDAQ:PAHC) Updates FY 2025 Earnings Guidance

Phibro Animal Health (NASDAQ:PAHC) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 1.870-2.010 for the period, compared to the consensus EPS estimate of 1.710. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion.

Phibro Animal Health Trading Up 0.9 %

Shares of NASDAQ:PAHC traded up $0.23 on Friday, reaching $24.81. 15,045 shares of the company traded hands, compared to its average volume of 146,596. Phibro Animal Health has a 52 week low of $10.03 and a 52 week high of $25.98. The stock has a market capitalization of $1.00 billion, a P/E ratio of 57.70, a price-to-earnings-growth ratio of 0.56 and a beta of 0.52. The company has a current ratio of 3.23, a quick ratio of 1.69 and a debt-to-equity ratio of 1.81. The business’s 50-day simple moving average is $21.87 and its 200 day simple moving average is $21.60.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.40 by $0.14. Phibro Animal Health had a return on equity of 21.59% and a net margin of 1.67%. As a group, equities analysts anticipate that Phibro Animal Health will post 1.62 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 26th. Stockholders of record on Wednesday, March 5th will be given a dividend of $0.12 per share. The ex-dividend date is Wednesday, March 5th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.93%. Phibro Animal Health’s payout ratio is currently 111.63%.

Wall Street Analyst Weigh In

PAHC has been the topic of several recent analyst reports. StockNews.com downgraded Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Barclays boosted their price objective on Phibro Animal Health from $13.00 to $20.00 and gave the company an “underweight” rating in a report on Tuesday, November 12th. Finally, Morgan Stanley boosted their price objective on Phibro Animal Health from $20.00 to $25.00 and gave the company an “equal weight” rating in a report on Tuesday, December 17th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, Phibro Animal Health presently has an average rating of “Hold” and an average price target of $20.50.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.